Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to improve colorectal cancer treatment

NCT ID NCT07150403

Not yet recruiting Disease control Sponsor: Federation Francophone de Cancerologie Digestive Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether a new drug called fruquintinib, combined with standard chemotherapy, can control advanced colorectal cancer better than the current standard treatment (bevacizumab plus chemotherapy). About 74 adults whose cancer has worsened after first-line therapy will be randomly assigned to one of the two combinations. The main goal is to see how many patients have their disease controlled at 4 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fruquintinib
What this could lead to
If successful, this could provide a new second-line treatment option for people with metastatic colorectal cancer.
What could go wrong
This is an early phase 2 trial with only 74 participants, so results may not apply to everyone. The drug may not work better than the current standard or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CARCINOMA (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CARCINOMA (MCRC)

Contacts and locations

Locations

  • BERGONIÉ

    Bordeaux, France

  • BRABOIS

    Vandœuvre-lès-Nancy, France

  • Bayeux Ch

    Bayeux, France

  • Beauvais Ch

    Beauvais, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • Centre Leonard de Vinci

    Dechy, France

  • Centre Pierre Curie

    Beuvry, France

  • Centre de Cancérologie du Grand Montpellier

    Montpellier, France

  • Ch Nord Ouest

    Villefranche-sur-Saône, France

  • Chauny Ch

    Chauny, France

  • Cholet Ch

    Cholet, France

  • Clinique Mutualiste de L'Estuaire

    Saint-Nazaire, France

  • Clinique de Flandre

    Coudekerque-Branche, France

  • Confluent Sas

    Nantes, France

  • Cote Basque

    Bayonne, France

  • Dijon Bourgogne

    Dijon, France

  • Docteur Schaffner

    Lens, France

  • Franco Britannique

    Levallois-Perret, France

  • GHPSO Site de Creil

    Creil, France

  • Ght Unyon Auxerre

    Auxerre, France

  • Groupe Hospitalier Diaconesses Croix Saint Simon

    Paris, France

  • Gustave Roussy

    Villejuif, France

  • Hopital Nord Chu Saint Etienne

    Saint-Priest-en-Jarez, France

  • Hôpital Européen G Pompidou

    Paris, France

  • ICAN Institut de Cancérologie de Strasbourg Europe

    Strasbourg, France

  • ICO Site Paul Papin

    Angers, France

  • ICO Site René Gauducheau

    Saint-Herblain, France

  • Institut de cancérologie de Bourgogne GRReCC

    Dijon, France

  • Jean Godinot

    Reims, France

  • Jean Mermoz

    Lyon, France

  • Jean Minjoz

    Besançon, France

  • LAYNÉ CH

    Mont-de-Marsan, France

  • LEMAN

    Thonon-les-Bains, France

  • La Miletrie

    Poitiers, France

  • La Pitié Salpêtrière

    Paris, France

  • La Timone

    Marseille, France

  • Les Bonnettes

    Arras, France

  • Robert Debré

    Reims, France

  • Saint Côme

    Compiègne, France

  • Saint Gregoire Chp

    Saint-Grégoire, France

  • Saint Louis

    Paris, France

  • Saint Malo Ch

    St-Malo, France

  • Sainte Anne

    Strasbourg, France

  • TIVOLI

    Bordeaux, France

  • Valence Ch

    Valence, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.